Beyond the Pharmaceutical Patent Arms Race
Over forty years after the Hatch-Waxman Act created a patent-based framework for balancing pharmaceutical innovation with competition, the system it established needs reform. We use data on pharmaceutical research and development over this four-decade period to argue that the current equilibrium is accurately characterized as an arms race of strategic legal activity. Brand-name firms amass […]